drugset / Trial / NCT05566028

The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes

NCT05566028

Phase 3 Completed 172 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.

Timeline

Start
2022-10-12
Primary completion
2024-01-10
Completion
2024-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject D745 Unknown